Voltaren switches to OTC status in the US

19 February 2020 - Deborah Wilkes

Archived

The US Food and Drug Administration (FDA) has switched GlaxoSmithKline’s (GSK’s) topical pain reliever Voltaren (diclofenac sodium topical gel 1%) from prescription-to-OTC status. GSK said the OTC version, called Voltaren Arthritis Pain, would be “available on US shelves in spring 2020”.

Click tags below for more information on topics:

GlaxoSmithKline Diclofenac

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: